Get the Stockscreener App
101.01
0.99%
0.3245
Rhythm Pharmaceuticals Inc stock is traded at $101.01, with a volume of 129.40K.
It is up +0.99% in the last 24 hours and down -7.80% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$100.69
Open:
$100.07
24h Volume:
129.40K
Relative Volume:
0.21
Market Cap:
$6.72B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-35.95
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+1.82%
1M Performance:
-7.80%
6M Performance:
+69.67%
1Y Performance:
+73.82%
1-Day Range:
$99.44
$102.61
1-Week Range:
$95.46
$102.70
52-Week Range:
$45.91
$116.00
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
101.08 | 6.72B | 136.86M | -168.69M | -113.49M | -2.81 |
|
ARGX
Argen X Se Adr
|
919.16 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.66 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
196.37 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
362.78 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.07 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Why retail investors favor Rhythm Pharmaceuticals Inc. stock2025 Analyst Calls & Low Risk High Reward Ideas - newser.com
Will Rhythm Pharmaceuticals Inc. (1RV) stock profit from automation waveJuly 2025 Update & Fast Gain Stock Trading Tips - newser.com
Is it time to cut losses on Rhythm Pharmaceuticals Inc.2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Can machine learning forecast Rhythm Pharmaceuticals Inc. recoveryWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Can Rhythm Pharmaceuticals Inc. (1RV) stock hold up in economic slowdownWeekly Gains Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flow2025 Institutional Moves & Verified Swing Trading Watchlists - newser.com
Can Rhythm Pharmaceuticals Inc. stock weather global recessionDividend Hike & Accurate Entry/Exit Alerts - newser.com
What to do if you’re stuck in Rhythm Pharmaceuticals Inc.2025 Momentum Check & Verified High Yield Trade Plans - newser.com
Is Rhythm Pharmaceuticals Inc. reversing from oversold territoryMarket Trend Report & Fast Entry Momentum Alerts - newser.com
Rhythm Pharmaceuticals at Guggenheim Conference: Strategic Insights on Obesity Treatment - Investing.com Australia
Visualizing Rhythm Pharmaceuticals Inc. stock with heatmapsMarket Volume Report & Growth Focused Investment Plans - newser.com
Will Rhythm Pharmaceuticals Inc. price bounce be sustainable2025 Market Overview & Breakout Confirmation Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. stock positioned for digital transformationMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Canaccord Genuity Raises Price Target for RYTM Amidst Continued 'Buy' Rating | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (RYTM) Showcases Promising Obesity Drug D - GuruFocus
FDA extends review period for Rhythm’s Imcivree - The Pharma Letter
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 - The Manila Times
Rhythm Pharma (NASDAQ: RYTM) presents 27.1% BMI drop with setmelanotide plus GLP-1 - Stock Titan
How resilient is Rhythm Pharmaceuticals Inc. stock in market downturnsQuarterly Trade Review & Risk Adjusted Buy/Sell Alerts - newser.com
Rhythm pharma down as FDA extends review period for Imcivree label expansion - MSN
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million - AOL.com
Rhythm Pharmaceuticals Q3 2025 Earnings Preview - MSN
Needham Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - MSN
Rhythm Pharmaceuticals stock dips as Goldman Sachs lowers price target - Investing.com India
Rhythm Pharmaceuticals stock dips as Goldman Sachs lowers price target By Investing.com - Investing.com UK
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):